Abstract
p53 and p73 genes are both activated in response to DNA damage to induce either cell cycle arrest or apoptosis, depending on the strength and the quality of the damaging stimulus. p53/p73 transcriptional activity must be tightly regulated to ensure that the appropriate biological response is achieved and to allow the cell to re-enter into the cell cycle after the damage has been repaired. In addition to multiple transcriptionally active (TA) isoforms, dominant negative (DN) variants, that lack the amino-terminal transactivation domain and function as trans-repressors of p53, p63 and p73, are expressed from a second internal promoter (P2-p73Pr). Here we show that, in response to a non apoptotic DNA damage induced by low doses of doxorubicin, p53 binds in vivo, as detected by a p53-specific chromatin immunoprecipitation assay, and activates the P2-p73 promoter. DN-p73α protein accumulates under the same conditions and exogenously expressed DN-p73α is able to counteract the p53-induced activation of the P2-p73Pr. These results suggest that DN-p73 may contribute to the autoregulatory loops responsible for the termination of p53/p73 responses in cells that do not undergo apoptosis. Accordingly, the activation of the P2-p73Pr is markedly enhanced in both p73−/− murine fibroblasts and in human cells in which p73 transcripts are selectively knocked-out by p73-specific small interfering RNAs.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Agami R, Blandino G, Oren M, Shaul Y . 1999 Nature 399: 809–813
Caplen NJ, Parrish S, Imani F, Fire A, Morgan RA . 2001 Proc. Natl. Acad. Sci. USA 98: 9742–9747
Costanzo A, Merlo P, Pediconi N, Fulco M, Sartorelli V, Cole PA, Fontemaggi G, Fanciulli M, Blandino G, Balsano C, Levrero M . 2002 Mol. Cell. 9: 175–186
De Laurenzi V, Costanzo A, Barcaroli D, Terrinoni A, Falco M, Annicchiarico-Petruzzelli M, Levrero M, Melino G . 1998 J. Exp. Med. 188: 1763–1768
De Laurenzi VD, Catani MV, Terrinoni A, Corazzari M, Melino G, Costanzo A, Levrero M, Knight RA . 1999 Cell Death Differ. 6: 389–390
Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T . 2001 Nature 411: 494–498
Gong JG, Costanzo A, Yang HQ, Melino G, Kaelin Jr WG, Levrero M, Wang JY . 1999 Nature 399: 806–809
Grob TJ, Novak U, Maisse C, Barcaroli D, Luthi AU, Pirnia F, Hugli B, Graber HU, De Laurenzi V, Fey MF, Melino G, Tobler A . 2001 Cell Death Differ. 8: 1213–1223
Hartwell LH, Kastan MB . 1994 Science 266: 1821–1828
Irwin M, Marin MC, Phillips AC, Seelan RS, Smith DI, Liu W, Flores ER, Tsai KY, Jacks T, Vousden KH, Kaelin Jr WG . 2000 Nature 407: 645–648
Ishimoto O, Kawahara C, Enjo K, Obinata M, Nukiwa T, Ikawa S . 2002 Cancer Res. 62: 636–641
Levrero M, De Laurenzi V, Costanzo A, Gong J, Melino G, Wang JY . 1999 Cell Death Differ. 6: 1146–1153
Levrero M, De Laurenzi V, Costanzo A, Gong J, Wang JY, Melino G . 2000 J. Cell. Sci. 113: 1661–1670
Liefer KM, Koster MI, Wang XJ, Yang A, McKeon F, Roop DR . 2000 Cancer Res. 60: 4016–4020
Lipardi C, Wei Q, Paterson BM . 2001 Cell 107: 297–307
Lissy NA, Davis PK, Irwin M, Kaelin WG, Dowdy SF . 2000 Nature 407: 642–645
Lohrum MAE, Vousden KH . 1999 Cell Death Differ. 6: 1162–1168
Nishikura K . 2001 Cell 107: 415–418
Oda K, Arakawa H, Tanaka T, Matsuda K, Tanikawa C, Mori T, Nishimori H, Tamai K, Tokino T, Nakamura Y, Taya Y . 2000 Cell 102: 849–862
Pozniak CD, Radinovic S, Yang A, McKeon F, Kaplan DR, Miller FD . 2000 Science 289: 304–306
Prives C, Hall PA . 1999 J. Pathol. 187: 112–126
Rich T, Allen RL, Wyllie AH . 2000 Nature 407: 777–783
Sayan AE, Sayan BS, Findikli N, Ozturk M . 2001 Oncogene 20: 5111–5117
Sijen T, Fleenor J, Simmer F, Thijssen KL, Parrish S, Timmons L, Plasterk RH, Fire A . 2001 Cell 107: 465–476
Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dotsch V, Andrews NC, Caput D, McKeon F . 1998 Mol. Cell 2: 305–316
Yuan ZM, Shioya H, Ishiko T, Sun X, Gu J, Huang YY, Lu H, Kharbanda S, Weichselbaum R, Kufe D . 1999 Nature 399: 814–817
Zhou BB, Elledge SJ . 2000 Nature 408: 433–439
Acknowledgements
This work was supported by grants from AIRC, MURST-Cofin, Telethon Projects A1072 and E1325 and Schering-Plough to M Levrero. S Vossio and F Moretti are supported by fellowships from the Fondazione A. Cesalpino. A Costanzo is supported by a Staff Scientist Grant from the Fondazione A. Cesalpino.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Vossio, S., Palescandolo, E., Pediconi, N. et al. DN-p73 is activated after DNA damage in a p53-dependent manner to regulate p53-induced cell cycle arrest. Oncogene 21, 3796–3803 (2002). https://doi.org/10.1038/sj.onc.1205465
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205465
Keywords
This article is cited by
-
The p53 family member p73 in the regulation of cell stress response
Biology Direct (2021)
-
The Dual Role of ROS in Hematological Malignancies: Stem Cell Protection and Cancer Cell Metastasis
Stem Cell Reviews and Reports (2020)
-
Diverse p63 and p73 isoforms regulate Δ133p53 expression through modulation of the internal TP53 promoter activity
Cell Death & Differentiation (2012)
-
Regulation of p73 activity by post-translational modifications
Cell Death & Disease (2012)
-
p53-paralog DNp73 oncogene is repressed by IFNα/STAT2 through the recruitment of the Ezh2 polycomb group transcriptional repressor
Oncogene (2011)